Cancer vaccine - Norsk Hydro

Drug Profile

Cancer vaccine - Norsk Hydro

Alternative Names: EMD 249590; Ras cancer vaccine - Norsk Hydro; Ras vaccine - Norsk Hydro

Latest Information Update: 03 Sep 2015

Price : $50

At a glance

  • Originator Norsk Hydro
  • Class Cancer vaccines
  • Mechanism of Action Ras signal transduction pathway modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Colorectal cancer; Non-small cell lung cancer; Pancreatic cancer

Most Recent Events

  • 29 Nov 2000 Merck KGaA has returned all rights to the Ras vaccine to Norsk Hydro
  • 06 Jul 2000 A phase II study in patients with pancreatic cancer has been added to the Cancer therapeutic trials section
  • 07 Jul 1999 Investigation in Colorectal cancer in Europe (Intradermal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top